Myovant Sciences (MYOV) Appoints Nancy Valente to its Board

Myovant Sciences (NYSE: MYOV), a healthcare company focused on redefining care for women and for men, today announced the appointment of Nancy Valente, M.D. as an independent member of the company’s Board of Directors. Dr. Valente is a renowned expert in hematology and oncology drug development with over 20 years of experience leading global development programs at Genentech/Roche and other leading pharmaceutical companies involving novel first-in-class molecules. In addition to her Board appointment, Dr. Valente will chair the Board’s Nominating and Corporate Governance Committee and be a member of the Audit Committee.

“We are excited to welcome Dr. Valente to our Board,” said David Marek, Chief Executive Officer of Myovant Sciences, Inc. “Her deep experience in drug development and impressive track record leading teams through successful regulatory approvals will be invaluable as Myovant continues to build its pipeline through lifecycle management and potential business development to enable long-term sustainable growth.”

In her most recent role, Dr. Valente was Senior Vice President and Co-lead for Global Product Development, Oncology, Hematology Development Therapeutic Area at Roche. In this role, she was responsible for setting the strategy for the department, clinical development, collaboration activities, and budget management. She played a critical role in the development of new therapies for patients with serious illnesses, including the approvals of GAZYVA®, VENCLEXTA®, POLIVY®, and HEMLIBRA®. Previously, she held various positions with increasing responsibilities at Genentech and then at Roche after Genentech was acquired by Roche, including Vice President for Global Product Development for Oncology, Hematology Franchise and Senior Group Medical Director, Leader for Hematology Development. Prior to Genentech, she served in senior-level positions at Anosys, Inc. and Coulter Pharmaceutical, Inc. Dr. Valente has held academic positions at the University of California, San Francisco (UCSF) where her most recent role was Assistant Adjunct Clinical Professor of Medicine specializing in breast cancer. Dr. Valente received her medical degree from the University of Missouri and completed her internal medicine training at Oregon Health & Science University, followed by fellowships in Hematology at Stanford University and Oncology at UCSF.

“I am honored to serve on the Board of Directors of Myovant Sciences,” said Dr. Valente. “Myovant has had tremendous success conducting global clinical trials that resulted in three regulatory approvals and product launches within the past 12 months. I look forward to supporting Myovant as it embarks on its exciting next phase of growth in expanding its pipeline and portfolio for patients who need new and effective treatment options.”

You May Also Be Interested In

• Ainos launches on-site nitrogen generator for AI and chip facilities
• ReElement gets air permits for Indiana rare earth refinery
• Complete Genomics names film producer Lauren Selig to its board